Cargando…

Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study

Objectives To investigate the risks of invasive cervical cancer after detection of atypical glandular cells (AGC) during cervical screening. Design Nationwide population based cohort study. Setting Cancer and population registries in Sweden. Participants 3 054 328 women living in Sweden at any time...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiangrong, Andrae, Bengt, Sundström, Karin, Ström, Peter, Ploner, Alexander, Elfström, K Miriam, Arnheim-Dahlström, Lisen, Dillner, Joakim, Sparén, Pär
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772788/
https://www.ncbi.nlm.nih.gov/pubmed/26869597
http://dx.doi.org/10.1136/bmj.i276
_version_ 1782418625411416064
author Wang, Jiangrong
Andrae, Bengt
Sundström, Karin
Ström, Peter
Ploner, Alexander
Elfström, K Miriam
Arnheim-Dahlström, Lisen
Dillner, Joakim
Sparén, Pär
author_facet Wang, Jiangrong
Andrae, Bengt
Sundström, Karin
Ström, Peter
Ploner, Alexander
Elfström, K Miriam
Arnheim-Dahlström, Lisen
Dillner, Joakim
Sparén, Pär
author_sort Wang, Jiangrong
collection PubMed
description Objectives To investigate the risks of invasive cervical cancer after detection of atypical glandular cells (AGC) during cervical screening. Design Nationwide population based cohort study. Setting Cancer and population registries in Sweden. Participants 3 054 328 women living in Sweden at any time between 1 January 1980 and 1 July 2011 who had any record of cervical cytological testing at ages 23-59. Of these, 2 899 968 women had normal cytology results at the first screening record. The first recorded abnormal result was atypical glandular cells (AGC) in 14 625, high grade squamous intraepithelial lesion (HSIL) in 65 633, and low grade squamous intraepithelial lesions (LSIL) in 244 168. Main outcome measures Cumulative incidence of invasive cervical cancer over 15.5 years; proportion of invasive cervical cancer within six months of abnormality (prevalence); crude incidence rates for invasive cervical cancer over 0.5-15.5 years of follow-up; incidence rate ratios compared with women with normal cytology, estimated with Poisson regression adjusted for age and stratified by histopathology of cancer; distribution of clinical assessment within six months after the abnormality. Results The prevalence of cervical cancer was 1.4% for women with AGC, which was lower than for women with HSIL (2.5%) but higher than for women with LSIL (0.2%); adenocarcinoma accounted for 73.2% of the prevalent cases associated with AGC. The incidence rate of invasive cervical cancer after AGC was significantly higher than for women with normal results on cytology for up to 15.5 years and higher than HSIL and LSIL for up to 6.5 years. The incidence rate of adenocarcinoma was 61 times higher than for women with normal results on cytology in the first screening round after AGC, and remained nine times higher for up to 15.5 years. Incidence and prevalence of invasive cervical cancer was highest when AGC was found at ages 30-39. Only 54% of women with AGC underwent histology assessment within six months, much less than after HSIL (86%). Among women with histology assessment within six months, the incidence rate of cervical cancer after AGC was significantly higher than that after HSIL for up to 6.5 years. Conclusions AGC found at cervical screening is associated with a high and persistent risk of cervical cancer for up to 15 years, particularly for cervical adenocarcinoma and women with AGC at age 30-39. Compared with the reduction in risk of cancer seen after HSIL management, management of AGC seems to have been suboptimal in preventing cervical cancer. Research to optimise management is needed, and a more aggressive assessment strategy is warranted.
format Online
Article
Text
id pubmed-4772788
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-47727882016-03-10 Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study Wang, Jiangrong Andrae, Bengt Sundström, Karin Ström, Peter Ploner, Alexander Elfström, K Miriam Arnheim-Dahlström, Lisen Dillner, Joakim Sparén, Pär BMJ Research Objectives To investigate the risks of invasive cervical cancer after detection of atypical glandular cells (AGC) during cervical screening. Design Nationwide population based cohort study. Setting Cancer and population registries in Sweden. Participants 3 054 328 women living in Sweden at any time between 1 January 1980 and 1 July 2011 who had any record of cervical cytological testing at ages 23-59. Of these, 2 899 968 women had normal cytology results at the first screening record. The first recorded abnormal result was atypical glandular cells (AGC) in 14 625, high grade squamous intraepithelial lesion (HSIL) in 65 633, and low grade squamous intraepithelial lesions (LSIL) in 244 168. Main outcome measures Cumulative incidence of invasive cervical cancer over 15.5 years; proportion of invasive cervical cancer within six months of abnormality (prevalence); crude incidence rates for invasive cervical cancer over 0.5-15.5 years of follow-up; incidence rate ratios compared with women with normal cytology, estimated with Poisson regression adjusted for age and stratified by histopathology of cancer; distribution of clinical assessment within six months after the abnormality. Results The prevalence of cervical cancer was 1.4% for women with AGC, which was lower than for women with HSIL (2.5%) but higher than for women with LSIL (0.2%); adenocarcinoma accounted for 73.2% of the prevalent cases associated with AGC. The incidence rate of invasive cervical cancer after AGC was significantly higher than for women with normal results on cytology for up to 15.5 years and higher than HSIL and LSIL for up to 6.5 years. The incidence rate of adenocarcinoma was 61 times higher than for women with normal results on cytology in the first screening round after AGC, and remained nine times higher for up to 15.5 years. Incidence and prevalence of invasive cervical cancer was highest when AGC was found at ages 30-39. Only 54% of women with AGC underwent histology assessment within six months, much less than after HSIL (86%). Among women with histology assessment within six months, the incidence rate of cervical cancer after AGC was significantly higher than that after HSIL for up to 6.5 years. Conclusions AGC found at cervical screening is associated with a high and persistent risk of cervical cancer for up to 15 years, particularly for cervical adenocarcinoma and women with AGC at age 30-39. Compared with the reduction in risk of cancer seen after HSIL management, management of AGC seems to have been suboptimal in preventing cervical cancer. Research to optimise management is needed, and a more aggressive assessment strategy is warranted. BMJ Publishing Group Ltd. 2016-02-11 /pmc/articles/PMC4772788/ /pubmed/26869597 http://dx.doi.org/10.1136/bmj.i276 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/.
spellingShingle Research
Wang, Jiangrong
Andrae, Bengt
Sundström, Karin
Ström, Peter
Ploner, Alexander
Elfström, K Miriam
Arnheim-Dahlström, Lisen
Dillner, Joakim
Sparén, Pär
Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study
title Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study
title_full Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study
title_fullStr Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study
title_full_unstemmed Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study
title_short Risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study
title_sort risk of invasive cervical cancer after atypical glandular cells in cervical screening: nationwide cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772788/
https://www.ncbi.nlm.nih.gov/pubmed/26869597
http://dx.doi.org/10.1136/bmj.i276
work_keys_str_mv AT wangjiangrong riskofinvasivecervicalcancerafteratypicalglandularcellsincervicalscreeningnationwidecohortstudy
AT andraebengt riskofinvasivecervicalcancerafteratypicalglandularcellsincervicalscreeningnationwidecohortstudy
AT sundstromkarin riskofinvasivecervicalcancerafteratypicalglandularcellsincervicalscreeningnationwidecohortstudy
AT strompeter riskofinvasivecervicalcancerafteratypicalglandularcellsincervicalscreeningnationwidecohortstudy
AT ploneralexander riskofinvasivecervicalcancerafteratypicalglandularcellsincervicalscreeningnationwidecohortstudy
AT elfstromkmiriam riskofinvasivecervicalcancerafteratypicalglandularcellsincervicalscreeningnationwidecohortstudy
AT arnheimdahlstromlisen riskofinvasivecervicalcancerafteratypicalglandularcellsincervicalscreeningnationwidecohortstudy
AT dillnerjoakim riskofinvasivecervicalcancerafteratypicalglandularcellsincervicalscreeningnationwidecohortstudy
AT sparenpar riskofinvasivecervicalcancerafteratypicalglandularcellsincervicalscreeningnationwidecohortstudy